Clinical Hematology International

Volume 3, Issue 4, December 2021, Pages 130 - 141

How I Use Measurable Residual Disease in the Clinical Management of Adult Acute Lymphoblastic Leukemia

Authors
Fiona Fernando, Harry Frederick Robertson, Sarah El-Zahab, Jiří Pavlů*
Centre for Haematology, Imperial College London at Hammersmith Hospital, London, UK

These two authors contributed equally to this work.

*Corresponding author. Email: jiri@pavlu.co.uk
Corresponding Author
Jiří Pavlů
Received 22 June 2021, Accepted 5 October 2021, Available Online 29 November 2021.
DOI
https://doi.org/10.2991/chi.k.211119.001How to use a DOI?
Keywords
ALL; MRD; acute lymphoblastic leukemia; measurable residual disease; adult
Abstract

Over the last decade the use of measurable residual disease (MRD) diagnostics in adult acute lymphoblastic leukemia (ALL) has expanded from a limited number of study groups in Europe and the United States to a world-wide application. In this review, we summarize the advantages and drawbacks of the current available techniques used for MRD monitoring. Through the use of three representative case studies, we highlight the advances in the use of MRD in clinical decision-making in the management of ALL in adults. We acknowledge discrepancies in MRD monitoring and treatment between different countries, reflecting differing availability, accessibility and affordability.

Copyright
© 2021 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V.
Open Access
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Download article (PDF)
View full text (HTML)

Journal
Clinical Hematology International
Volume-Issue
3 - 4
Pages
130 - 141
Publication Date
2021/11/29
ISSN (Online)
2590-0048
DOI
https://doi.org/10.2991/chi.k.211119.001How to use a DOI?
Copyright
© 2021 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V.
Open Access
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Cite this article

TY  - JOUR
AU  - Fiona Fernando
AU  - Harry Frederick Robertson
AU  - Sarah El-Zahab
AU  - Jiří Pavlů
PY  - 2021
DA  - 2021/11/29
TI  - How I Use Measurable Residual Disease in the Clinical Management of Adult Acute Lymphoblastic Leukemia
JO  - Clinical Hematology International
SP  - 130
EP  - 141
VL  - 3
IS  - 4
SN  - 2590-0048
UR  - https://doi.org/10.2991/chi.k.211119.001
DO  - https://doi.org/10.2991/chi.k.211119.001
ID  - Fernando2021
ER  -